Skip to main content

Guardant Health, Inc.

For the period ended Jun 30, 2026. Filed Jul 30, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 30, 2026

GH$155.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except per share data)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$334,978$232,088$636,643$435,559
Costs and operating expenses:
Cost of revenue115,94981,205220,868155,928
Research and development expense96,53387,449187,571175,970
Sales and marketing expense189,954119,588359,086223,904
General and administrative expense61,66050,259119,58697,211
Total costs and operating expenses464,096338,501887,111653,013
Loss from operations(129,118)(106,413)(250,468)(217,454)
Interest income10,1997,56021,35016,672
Interest expense(1,346)(983)(2,693)(1,774)
Other income (expense), net308(25)1517,826
Loss before provision for income taxes(119,957)(99,861)(231,660)(194,730)
Provision for income taxes18538557328
Net loss$(120,142)$(99,899)$(232,217)$(195,058)
Net loss per share, basic and diluted$(0.90)$(0.80)$(1.76)$(1.57)
Weighted-average shares used in computing net loss per share, basic and diluted132,867124,114132,074123,993
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.